Cameron Santoro

The top 5 biosimilar articles touch on the growing biosimilar landscape, including recent FDA approvals, patent disputes, cost-saving potential, and challenges in market entry.

Racial and ethnic disparities are found among Asian individuals as they experience the highest lifetime incidence of alopecia areata, and Black individuals face a disproportionately higher risk of anxiety disorders associated with the condition.

Mikael Eriksson, PhD, epidemiologist at Karolinska Institute in Sweden, discusses the development and implementation of an artificial intelligence (AI) model to reduce bias and improve breast cancer prevention.

Roberto Salgado, MD, anatomic pathologist for breast cancer translational research at Institut Jules Bordet, examines the significance of tumor-infiltrating lymphocytes (TILs) in various breast cancer types and emphasizes the need for standardized TIL evaluation methods to improve patient outcomes.

The FDA granted approval to Steqeyma (ustekinumab-stba) for inflammatory conditions, making it the seventh biosimilar to reference Stelara after a year of multiple ustekinumab biosimilar approvals.

Here are 5 key points on electronic cigarette use that cover industry marketing methods, harmful substances, associated health risks, regulations, and its links to mental health as well as the COVID-19 pandemic.

The top 5 podcasts for 2024 cover Medicare Advantage prior authorization, health equity, global immunization challenges, trauma-informed care, and health literacy.

The FDA has approved ensartinib in adult patients with anaplastic lymphoma kinase (ALK)–positive locally advanced or metastatic non–small cell lung cancer (NSCLC) naive to ALK treatment.

Cognitive and behavioral techniques can improve physical function and overall well-being in patients with long COVID.

The most-read breast cancer articles include topics on hereditary breast cancer, hormone therapy benefits, BRCA mutations, as well as treatment outcomes.

The most-read alopecia articles include topics on Janus kinase inhibitors, new therapeutic strategies, health-related quality of life measurements, potential links to the COVID-19 vaccine, and disease pathogenesis.

The most-read gene therapy articles included topics on FDA approvals, chimeric antigen receptor T-cell therapies, the cost-effectiveness of gene therapies, as well as other findings.

Inadequate housing significantly impacts public health, leading to various health issues and increased mortality rates.

Breast cancer outcomes are significantly impacted by race and immune responses, particularly among Black patients with triple-negative subtypes, emphasizing the need to understand these disparities and develop more effective treatment strategies.

Patients with ER-positive/HER2-negative metastatic breast cancer who received elacestrant experienced a significant reduction in disease progression or death compared with standard-of-care endocrine therapy.

Komal Jhaveri, MD, FACP, breast oncologist and early drug development specialist at Memorial Sloan Kettering Cancer Center, presents findings from the EMBER-3 trial evaluating imlunestrant for patients with advanced breast cancer.

COVID-19 infections were associated with greater risk of hospitalization, complications, and mortality in patients with peripartum and hypertrophic cardiomyopathy.

Tirzepatide and semaglutide, both medications for obesity treatment, demonstrate similar safety and efficacy but tirzepatide resulted in greater levels of weight loss among patients compared with semaglutide.

Panelists proposed policy solutions to ensure long-term sustainability of infused biosimilars amid current challenges, including average sales price erosion and reimbursement issues.

Deuruxolitinib showed significant efficacy and safety in hair regrowth stimulation among adult patients with alopecia areata, particularly in those with moderate to severe hair loss.

Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) compared with standard-of-care treatments for patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer.

Food insecurity is a significant public health concern that disproportionately affects marginalized communities, contributing to a range of health disparities.

Patients with treatment-resistant central centrifugal cicatricial alopecia saw improvement in symptoms and gene expression, suggesting the potential of metformin as a new treatment option.

Younger women with estrogen receptor (ER)–positive, HER2-negative breast cancer have significantly worse long-term outcomes, including higher rates of recurrence and metastasis, compared with older women.

Global Biosimilars Week discussed issues in biosimilar adoption and called for reforms to streamline processes, foster competition, and increase biosimilar access for patients.

Currently, chemotherapy remains a common treatment for biliary tract cancers, which have a limited survival rate.